Your results have been filtered for all content within all Money Map Press subscriptions

On Wednesday, we discussed why investors shouldn't be surprised when the Dow turned downward sharply on Friday. Sure enough, the markets dipped more than 100 points after the U.S. Commerce Department revised its first quarter GDP figure and said that the economy retracted by 0.7% for the March-ending quarter.

After that dismal figure was reported, both economists and sympathetic apologists turned the spin cycle on high.

On CNBC Friday morning, one commentator asked if this revision wasn't so bad... because economists were expecting -0.8%, and the reading was -0.7%.  By beating dismal expectations and inching over an already sunken bar, America won in the pundits' hive-mind.

Meanwhile, MarketWatch called the GDP reversal a "First Quarter Shocker."

 
Your current subscriptions do not allow access to this search result.
Learn More

Crude oil has been on the move higher. But, it's unlikely to go too much higher.

Both West Texas Intermediate (WTI) from the United States and Brent, a classification name for light sweet crude from the North Sea, have recovered from their lows.

For WTI, which is the American benchmark and what's mostly traded in the United States, that bounce-back high is a little over $60 a barrel. Right now, WTI is trading at $59.58.

We're going to short WTI because on a risk/reward basis shorting it at its high and giving ourselves more room for it to stretch higher, makes sense. And because it doesn't make sense to expect crude to go a lot higher from here.

 
Your current subscriptions do not allow access to this search result.
Learn More

I'm on the road today, but our Stealth Stock Trading Indicator (SSTI) has signaled an entry in the Emerging Markets, and I wanted to get this out to you quickly.

As you can see below, the EEM ETF has pulled back to its 200-day moving average:

I'm not expecting the Emerging Markets to make a quick run back up to their April highs, but the SSTI is showing that the rubber band is very stretched and due for a quick snap back. We'll use the leveraged ETF EDC for the stock play and use EEM calls to help manage the volatility.

 
Your current subscriptions do not allow access to this search result.
Learn More

Today's recommendation is a bit unusual. We added Uranium Energy Corp. (NYSE MKT:UEC) to the Portfolio on February 17. This morning it has reached a profit of 102%.

But we have also added a number of new members over the past month. Therefore, the move suggested today is only for those folks who have been in the stock since its introduction.

UEC has improved 21% over the past month, and that is certainly nice. But newer members should not sell now. Let it accumulate and I'll advise when to take profits.

 
Your current subscriptions do not allow access to this search result.
Learn More

Before we get to today's alert, I have a slight correction to make. In yesterday's alert, regarding XOMA Corp. (NasdaqGM:XOMA), I said our catalyst, the data release from the first part of the EYEGUARD-B Phase 3 study of gevokizumab in the treatment of Behcet's uveitis, would take place in seven weeks, "...sometime around June 16." That should have read, "...sometime around July 16." Sorry for the confusion.

XOMA, which had been foundering lately on no news, is up more than 8% since the company's announcement that the last exacerbation had taken place among uveitis patients in the study, which will now allow statisticians to move forward in analyzing the data.  

We'll keep an eye on share price over the next few weeks and make some decisions about how to handle the stock as the catalyst approaches.

 
Your current subscriptions do not allow access to this search result.
Learn More

Two profit moves this morning. Harvest Natural Resources Inc. (NYSE:HNR) closed yesterday up 104% since we introduced it to the Portfolio only two weeks ago!

That marks our second 100% gain in a little over a week. Once again, I am recommending that you sell half of your position this morning and take the profits. Keep the remainder at the current trailing stop. That guarantees a nice profit on the final 50% of your position regardless of what happens from this point forward.

The second move is obliged by a very unusual event yesterday. Transportadora de Gas Del Sur SA (NYSE:TGS), our Argentinian natural gas pipeline company, had been performing quite nicely. However, there was a brief major decline in price yesterday only to be followed by an even greater recovery.

 
Your current subscriptions do not allow access to this search result.
Learn More

Normally investors don't use the words "small cap" and "value" in the same sentence, but that's exactly what I've found for you today... a small-cap value play with plenty of upside potential.

Identifying such stocks isn't easy. You've got to have one or more "sparks" - earnings, management, a change in product lines, for example - and a compelling reason to make your move.

JAKKS Pacific Inc. (NasdaqGS:JAKK) fits.

Most investors have never heard of the company, but they are certainly familiar with its products. That's because JAKKS designs, produces, and sells consumer action figures and toys based on some of the most successful franchises of all time and has since 1995.

 
Your current subscriptions do not allow access to this search result.
Learn More

Due to an aging population, surging costs and a boom in chronic diseases, we spend an astounding 18% of our gross domestic product (GDP) on healthcare here in the United States.

And as the healthcare sector expands almost beyond belief, its tech cousin - digital health - is exploding right along with it.

Digital health is where the worlds of technology and healthcare converge. When healthcare professionals and patients put wearable tech, sensors, Big Data and genomics to use... that's digital health. It aims to reduce inefficiencies and costs and improves access and quality by empowering healthcare professionals and ourselves to better track, manage and improve our health.

 
Your current subscriptions do not allow access to this search result.
Learn More

We've finally received some news regarding XOMA Corp. (NasdaqGM:XOMA). 

The company announced today that the final exacerbation of Behcet's uveitis in the EYEGUARD-B phase 3 study of its experimental drug gevokizumab has occurred. This signals the end of the first part of the ongoing study, which will assess both the effectiveness and safety of the drug.

Behcet's disease is an auto-inflammatory disease of unknown cause that damages blood vessels throughout the body. When it causes inflammation in the eyes, it can lead to blindness.

 
Your current subscriptions do not allow access to this search result.
Learn More

I saw a statistic in the Wall Street Journal a few days ago that alarmed me. ATM data theft has soared some 317% in the first few months of 2015.

As someone who's had his credit cards hacked several times, I have to say that even I was surprised at the sheer scale data thieves can accomplish.

The credit reporting agency FICO says that from January to April 9, the number of attacks on debit cards reached a 20-year high.

Criminals are coming up with creative new ways to install "skimming" devices onto ATMs that capture information from the card's magnetic stripe.

 
Your current subscriptions do not allow access to this search result.
Learn More